{"id":332055,"date":"2026-10-29T13:01:14","date_gmt":"2026-10-29T07:31:14","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=332055"},"modified":"2026-10-29T13:01:14","modified_gmt":"2026-10-29T07:31:14","slug":"active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/","title":{"rendered":"3 Active Ingredients and Custom Manufacturing Specialist, Paracetamol and Formulations Leader and Crop Science Innovator Stocks With a Strong Future Roadmap: Neuland Laboratories, Granules India and PI Industries"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Neuland Laboratories, Granules India and PI Industries: ROE of 11.7% to 19.4% and FY22 to FY26 revenue CAGR of 6.8% to 21.1%. Prices as of 28 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three API, formulations and crop science stocks to watch are Neuland Laboratories, Granules India and PI Industries. Their return on equity ranges from 11.7% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 21.1%. Neuland Laboratories leads on both return on equity at 19.4% and revenue growth at 21.1% a year. Prices are based on the 28 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>API, formulations and crop science stocks let investors follow companies that serve a growing part of the Indian economy. Neuland Laboratories, Granules India and PI Industries cover an active ingredients and custom manufacturing specialist, a paracetamol and formulations leader and a crop science innovator.<\/p>\n<p>This list covers three API, formulations and crop science stocks with complete current figures: Neuland Laboratories, Granules India and PI Industries. Every figure comes from the latest reported financials and the 28 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#What_Are_API_Formulations_and_Crop_Science_Stocks\" title=\"What Are API, Formulations and Crop Science Stocks?\">What Are API, Formulations and Crop Science Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#API_Formulations_and_Crop_Science_Stocks_at_a_Glance\" title=\"API, Formulations and Crop Science Stocks at a Glance\">API, Formulations and Crop Science Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#Why_Do_API_Formulations_and_Crop_Science_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do API, Formulations and Crop Science Stocks Have a Strong Roadmap in India?\">Why Do API, Formulations and Crop Science Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#Why_Neuland_Laboratories_Features_Among_These_API_Formulations_and_Crop_Science_Stocks\" title=\"Why Neuland Laboratories Features Among These API, Formulations and Crop Science Stocks\">Why Neuland Laboratories Features Among These API, Formulations and Crop Science Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#Why_Granules_India_Features_Among_These_API_Formulations_and_Crop_Science_Stocks\" title=\"Why Granules India Features Among These API, Formulations and Crop Science Stocks\">Why Granules India Features Among These API, Formulations and Crop Science Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#Why_PI_Industries_Features_Among_These_API_Formulations_and_Crop_Science_Stocks\" title=\"Why PI Industries Features Among These API, Formulations and Crop Science Stocks\">Why PI Industries Features Among These API, Formulations and Crop Science Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#Neuland_Laboratories_vs_Granules_India_vs_PI_Industries_on_Key_Financials\" title=\"Neuland Laboratories vs Granules India vs PI Industries on Key Financials\">Neuland Laboratories vs Granules India vs PI Industries on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#Key_Risks_to_Check_Before_Investing_in_API_Formulations_and_Crop_Science_Stocks\" title=\"Key Risks to Check Before Investing in API, Formulations and Crop Science Stocks\">Key Risks to Check Before Investing in API, Formulations and Crop Science Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#Final_Thoughts_on_API_Formulations_and_Crop_Science_Stocks\" title=\"Final Thoughts on API, Formulations and Crop Science Stocks\">Final Thoughts on API, Formulations and Crop Science Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#What_are_API_formulations_and_crop_science_stocks\" title=\"What are API, formulations and crop science stocks?\">What are API, formulations and crop science stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#Which_API_formulations_and_crop_science_stocks_are_covered_in_this_list\" title=\"Which API, formulations and crop science stocks are covered in this list?\">Which API, formulations and crop science stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#Why_do_API_formulations_and_crop_science_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do API, formulations and crop science stocks have a strong future roadmap in India?\">Why do API, formulations and crop science stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#How_has_Neuland_Laboratories_performed_financially\" title=\"How has Neuland Laboratories performed financially?\">How has Neuland Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#How_has_Granules_India_performed_financially\" title=\"How has Granules India performed financially?\">How has Granules India performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#How_has_PI_Industries_performed_financially\" title=\"How has PI Industries performed financially?\">How has PI Industries performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#What_risks_should_investors_check_before_buying_API_formulations_and_crop_science_stocks\" title=\"What risks should investors check before buying API, formulations and crop science stocks?\">What risks should investors check before buying API, formulations and crop science stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/active-ingredients-and-custom-manufacturing-specialist-paracetamol-and-formulations-leader-and-crop-science-innovator-stocks-roadmap-pathfinder-list\/#Is_this_list_of_API_formulations_and_crop_science_stocks_investment_advice\" title=\"Is this list of API, formulations and crop science stocks investment advice?\">Is this list of API, formulations and crop science stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_API_Formulations_and_Crop_Science_Stocks\"><\/span><strong>What Are API, Formulations and Crop Science Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>API, formulations and crop science stocks are listed companies that make active pharmaceutical ingredients and supply innovator companies through custom manufacturing, produce intermediates and finished dosage forms and sell crop protection products while making complex molecules for global innovators. Their earnings depend on export orders, approvals and product mix.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"API_Formulations_and_Crop_Science_Stocks_at_a_Glance\"><\/span><strong>API, Formulations and Crop Science Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/neulandlab\/neuland-laboratories-ltd-share-price-today\">Neuland Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19,970<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24,665<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">49.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.16<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/granules\/granules-india-ltd-share-price-today\">Granules India<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">840.45<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22,002<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.30<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/piind\/pi-industries-ltd-share-price-today\">PI Industries<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,055<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33,166<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">28.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.03<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Granules India trades at a P\/E below the industry P\/E, while Neuland Laboratories and PI Industries trade above it, which reflects the growth the market already expects. Readers comparing API, formulations and crop science stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_API_Formulations_and_Crop_Science_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do API, Formulations and Crop Science Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>API, formulations and crop science stocks have a strong roadmap in India because global firms keep outsourcing complex manufacturing to India and demand for generics and crop protection stays steady across markets.<\/p>\n<ul>\n<li><strong>Outsourcing trend.<\/strong> Global firms add Indian partners.<\/li>\n<li><strong>Scale benefits.<\/strong> Large plants support volume leadership.<\/li>\n<li><strong>Innovator ties.<\/strong> Custom work builds long term relationships.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Neuland_Laboratories_Features_Among_These_API_Formulations_and_Crop_Science_Stocks\"><\/span><strong>Why Neuland Laboratories Features Among These API, Formulations and Crop Science Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the API, formulations and crop science stocks on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.<\/p>\n<p>Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.<\/p>\n<p>The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P\/E of 49.5, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.<\/p>\n<p><strong>What to watch:<\/strong> Custom manufacturing revenue can move between quarters, so review the full-year trend.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Granules_India_Features_Among_These_API_Formulations_and_Crop_Science_Stocks\"><\/span><strong>Why Granules India Features Among These API, Formulations and Crop Science Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the contract manufacturing shares on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.<\/p>\n<p>The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P\/E of 33.2, below the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.<\/p>\n<p><strong>What to watch:<\/strong> Monitor new product approvals and the share of finished dosages in total sales.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_PI_Industries_Features_Among_These_API_Formulations_and_Crop_Science_Stocks\"><\/span><strong>Why PI Industries Features Among These API, Formulations and Crop Science Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, PI Industries is a Udaipur-based agrochemical and custom synthesis company. It sells crop protection products in India and manufactures complex molecules for global innovators, and it has added pharma and specialty chemistry capabilities.<\/p>\n<p>Revenue rose from Rs 5,401 crore in FY22 to Rs 7,024 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 844 crore in FY22 to Rs 1,321 crore in FY26, which works out to a compound annual growth rate of 11.9%.<\/p>\n<p>The company has a return on equity of 11.8%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 33,166 crore. The stock trades at a P\/E of 28.5, above the industry P\/E of 23.3.<\/p>\n<p><strong>Roadmap:<\/strong> The company is building long-term supply contracts for global customers, launching new crop protection brands and widening into pharma and other specialty areas. Strong research and plant capacity support its pipeline.<\/p>\n<p><strong>What to watch:<\/strong> Check the growth of custom synthesis orders and new product launches.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Neuland_Laboratories_vs_Granules_India_vs_PI_Industries_on_Key_Financials\"><\/span><strong>Neuland Laboratories vs Granules India vs PI Industries on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three API, formulations and crop science stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Neuland Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">953<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,053<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">364<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Granules India<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,783<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,386<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.2%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">595<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">PI Industries<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,401<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,024<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6.8%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,321<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Neuland Laboratories posts the highest return on equity in this group at 19.4%. PI Industries has the largest FY26 revenue at Rs 7,024 crore, and Neuland Laboratories shows the fastest revenue growth with a 21.1% compound annual rate. A useful habit with API, formulations and crop science stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_API_Formulations_and_Crop_Science_Stocks\"><\/span><strong>Key Risks to Check Before Investing in API, Formulations and Crop Science Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these API, formulations and crop science stocks, the main points are:<\/p>\n<ul>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Currency moves.<\/strong> Export earnings move with the rupee.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter API, formulations and crop science stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_API_Formulations_and_Crop_Science_Stocks\"><\/span><strong>Final Thoughts on API, Formulations and Crop Science Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>API, formulations and crop science stocks reward investors who follow demand trends, order books and margins together. Neuland Laboratories, Granules India and PI Industries each have a clear plan to grow. Based on the 28 October 2026 close, Neuland Laboratories trades at Rs 19,970, Granules India at Rs 840.45 and PI Industries at Rs 2,055.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track API, formulations and crop science stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_API_formulations_and_crop_science_stocks\"><\/span><strong>What are API, formulations and crop science stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> API, formulations and crop science stocks are listed companies that make active pharmaceutical ingredients and supply innovator companies through custom manufacturing, produce intermediates and finished dosage forms and sell crop protection products while making complex molecules for global innovators. Their earnings depend on export orders, approvals and product mix. This list looks at three of them, Neuland Laboratories, Granules India and PI Industries, using reported FY22 to FY26 financials and the 28 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_API_formulations_and_crop_science_stocks_are_covered_in_this_list\"><\/span><strong>Which API, formulations and crop science stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Neuland Laboratories, Granules India and PI Industries. Based on the 28 October 2026 close, Neuland Laboratories traded at Rs 19,970, Granules India at Rs 840.45 and PI Industries at Rs 2,055. Their return on equity ranges from 11.7% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 21.1%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_API_formulations_and_crop_science_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do API, formulations and crop science stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> API, formulations and crop science stocks have a strong roadmap in India because global firms keep outsourcing complex manufacturing to India and demand for generics and crop protection stays steady across markets. The main drivers are as follows. Outsourcing trend. Global firms add Indian partners. Scale benefits. Large plants support volume leadership. Innovator ties. Custom work builds long term relationships. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Neuland_Laboratories_performed_financially\"><\/span><strong>How has Neuland Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P\/E of 49.5, above the industry P\/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Granules_India_performed_financially\"><\/span><strong>How has Granules India performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P\/E of 33.2, below the industry P\/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_PI_Industries_performed_financially\"><\/span><strong>How has PI Industries performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,401 crore in FY22 to Rs 7,024 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 844 crore in FY22 to Rs 1,321 crore in FY26, which works out to a compound annual growth rate of 11.9%. The company has a return on equity of 11.8%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 33,166 crore. The stock trades at a P\/E of 28.5, above the industry P\/E of 23.3. Looking ahead, the company is building long-term supply contracts for global customers, launching new crop protection brands and widening into pharma and other specialty areas. Strong research and plant capacity support its pipeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_API_formulations_and_crop_science_stocks\"><\/span><strong>What risks should investors check before buying API, formulations and crop science stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying API, formulations and crop science stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_API_formulations_and_crop_science_stocks_investment_advice\"><\/span><strong>Is this list of API, formulations and crop science stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 28 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are API, formulations and crop science stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"API, formulations and crop science stocks are listed companies that make active pharmaceutical ingredients and supply innovator companies through custom manufacturing, produce intermediates and finished dosage forms and sell crop protection products while making complex molecules for global innovators. Their earnings depend on export orders, approvals and product mix. This list looks at three of them, Neuland Laboratories, Granules India and PI Industries, using reported FY22 to FY26 financials and the 28 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which API, formulations and crop science stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Neuland Laboratories, Granules India and PI Industries. Based on the 28 October 2026 close, Neuland Laboratories traded at Rs 19,970, Granules India at Rs 840.45 and PI Industries at Rs 2,055. Their return on equity ranges from 11.7% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 21.1%.\"}},{\"@type\":\"Question\",\"name\":\"Why do API, formulations and crop science stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"API, formulations and crop science stocks have a strong roadmap in India because global firms keep outsourcing complex manufacturing to India and demand for generics and crop protection stays steady across markets. The main drivers are as follows. Outsourcing trend. Global firms add Indian partners. Scale benefits. Large plants support volume leadership. Innovator ties. Custom work builds long term relationships. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Neuland Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P\/E of 49.5, above the industry P\/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.\"}},{\"@type\":\"Question\",\"name\":\"How has Granules India performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P\/E of 33.2, below the industry P\/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.\"}},{\"@type\":\"Question\",\"name\":\"How has PI Industries performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,401 crore in FY22 to Rs 7,024 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 844 crore in FY22 to Rs 1,321 crore in FY26, which works out to a compound annual growth rate of 11.9%. The company has a return on equity of 11.8%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 33,166 crore. The stock trades at a P\/E of 28.5, above the industry P\/E of 23.3. Looking ahead, the company is building long-term supply contracts for global customers, launching new crop protection brands and widening into pharma and other specialty areas. Strong research and plant capacity support its pipeline.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying API, formulations and crop science stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying API, formulations and crop science stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of API, formulations and crop science stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 28 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>API, Formulations and Crop Science Stocks with a strong future roadmap: Neuland Laboratories, Granules India and PI Industries. Compare price, valuation, return on equity and revenue growth as of 28 October 2026.<\/p>\n","protected":false},"author":29,"featured_media":332054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[15449,3803,18091,18090,9050,8590,18092,6967],"class_list":["post-332055","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-api","tag-best-stocks","tag-contract-manufacturing-shares","tag-formulations-and-crop-science-stocks","tag-granules-india","tag-neuland-laboratories","tag-outsourcing-partner-stocks","tag-pi-industries"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["332054"],"rank_math_title":["Active Ingredients, Formulations and Crop Science Stocks"],"rank_math_description":["Compare 3 API, formulations and crop science stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 28 Oct 2026."],"rank_math_focus_keyword":["API, formulations and crop science stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-active-ingredients-and-custom-manufacturing-specialist-paracetamol-and.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/332055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=332055"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/332055\/revisions"}],"predecessor-version":[{"id":332056,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/332055\/revisions\/332056"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/332054"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=332055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=332055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=332055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}